Catalyst

Slingshot members are tracking this event:

Celgene (CELG) Announces Phase 1b Top-Line Data From CD-001 Evaluating GED-0301 in Patients with Active Crohn's Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CELG

100%
GLPG

100%

Additional Information

Additional Relevant Details "Galapagos NV is up on modestly higher volume in early trading. The bullish action is being stoked by increased optimism with Crohn's disease (CD) candidate filgotinib after Celgene  released early-stage data on its CD candidate GED-0301."
http://seekingalpha....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 16, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Endoscopy Trial, Cd-001, Ged-0301, Crohn's Disease